We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.14B
1-Year Est. Return
48.66%
This Fund
S&P 500
This Quarter
Est. Return
+11.1%
1 Year Est. Return
+48.66%
3 Year Est. Return
+137.63%
5 Year Est. Return
+227.94%
10 Year Est. Return
+772.14%
AUM
$292M
AUM Growth
+$16.8M
(+6.1%)
Cap. Flow
-$7.89M
Cap. Flow
% of AUM
-2.7%
Top 10 Holdings %
Top 10 Hldgs %
29.91%
Holding
120
New
8
Increased
27
Reduced
29
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$12.2M |
| 2 |
Arrowhead Research
ARWR
|
+$3.01M |
| 3 |
Biogen
BIIB
|
+$2.76M |
| 4 |
Gilead Sciences
GILD
|
+$1.62M |
| 5 |
Baidu
BIDU
|
+$1.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$6.53M |
| 2 |
Celldex Therapeutics
CLDX
|
+$6.14M |
| 3 |
YHOO
Yahoo Inc
YHOO
|
+$5.12M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$4.85M |
| 5 |
Noodles & Co
NDLS
|
+$2.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.95% |
| 2 | Energy | 16.91% |
| 3 | Communication Services | 13.82% |
| 4 | Industrials | 9.86% |
| 5 | Consumer Discretionary | 8.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Sprott Physical Gold and Silver Trust
CEF
$7.99B
| – | – |
-77,900
| Closed | -$1.15M |
|
|
102
Celldex Therapeutics
CLDX
$3.07B
| – | – |
-11,546
| Closed | -$6.14M |
|
|
103
Noodles & Co
NDLS
$88.2M
| – | – |
-7,686
| Closed | -$2.64M |
|
104
Regeneron Pharmaceuticals
REGN
$81.8B
| – | – |
-4,820
| Closed | -$1.51M |
|
|
SSKN
105
DELISTED
Strata Skin Sciences
SSKN
| – | – |
-83
| Closed | -$30K |
|
|
NSLR
106
Neostellar Capital Corp
NSLR
$270M
| – | – |
-15,401
| Closed | -$148K |
|
|
CLVS
107
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-36,600
| Closed | -$2.23M |
|
|
MNDT
108
DELISTED
Mandiant, Inc. Common Stock
MNDT
| – | – |
-50,000
| Closed | -$2.08M |
|
|
NUAN
109
DELISTED
Nuance Communications, Inc.
NUAN
| – | – |
-57,885
| Closed | -$936K |
|
|
YHOO
110
DELISTED
Yahoo Inc
YHOO
| – | – |
-154,200
| Closed | -$5.12M |
|
|
VVUS
111
DELISTED
Vivus Inc
VVUS
| – | – |
-10,000
| Closed | -$930K |
|
|
SDR
112
DELISTED
SANDRIDGE MISSISSIPPIAN TRUST II
SDR
| – | – |
-123,600
| Closed | -$1.62M |
|
Similar funds
SC
MIG
PC
RIM
VCP
HGIM
CAM
SIM
Private Capital Advisors's Q4 2013 Portfolio in Review
As of Q4 2013, Private Capital Advisors held 120 positions worth $292M, up 6.1% from $275M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Private Capital Advisors's Q4 2013 filing shows 8 new, 27 increased, 29 reduced and 13 closed positions. Its largest new stake was SANGAMO THERAPEUTICS INC: 1,059,000 shares worth $14.7M. The largest sale was BioMarin Pharmaceuticals, an estimated $6.53M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 20% a quarter earlier, followed by Energy and Communication Services.
- Private Capital Advisors's largest Q4 2013 buy was SANGAMO THERAPEUTICS INC: 1,059,000 shares worth $14.7M.
- Private Capital Advisors added most to Biogen in Q4 2013, an estimated $2.76M increase.
- Private Capital Advisors's biggest Q4 2013 reduction was Alphabet (Google) Class C, cutting an estimated $4.85M.
- Private Capital Advisors fully exited BioMarin Pharmaceuticals in Q4 2013, selling an estimated $6.53M.
- Private Capital Advisors's ten largest holdings make up 30% of its $292M portfolio in Q4 2013.
- Private Capital Advisors opened 8 new positions and closed 13 in Q4 2013.
- Private Capital Advisors's portfolio value rose 6.1% quarter-over-quarter to $292M.
Based on Private Capital Advisors's 13F filing for Q4 2013, filed 31 Jan 2014.